

Adult Headache Primary Care Pathway



Adult Headache Pathway



NHS Doncaster CCG Adult Chronic Headache Pathway With Open Access to CT Scanning

The following information is to support prescribers regarding the medicines aspects of the pathway, please refer to the BNF or Summary of Product Characteristics for further information on contraindications, precautions, adverse effects and interactions.

These guidelines have been developed using both British Association for the Study of Headache (BASH 2010) and NICE Headache (2012) guidelines.

Treatment of acute migraine

A stepped approach is often recommended commencing as early as possible with an analgesic and anti-emetics/pro-kinetic if required, and escalating to a 5HT1 receptor agonist (triptan) if this approach fails.

Aspirin or ibuprofen with or without paracetamol	Need to establish therapeutic levels quickly aspirin 600-900mg or ibuprofen 400-600mg paracetamol 1g
Metoclopramide	metoclopramide 10mg
Aspirin plus metoclopramide	Aspirin 900mg plus Metoclopramide 10mg, maximum three times a day (prescribe as individual drug)
Paracetamol plus metoclopramide	Paracetamol 500mg plus Metoclopramide 5mg (prescribe as individual drug)
Diclofenac suppositories	Diclofenac 50mg or 100mg – see notes below

Notes:

- 1. Please be aware of recent MHRA guidance on the use of <u>anti-emetics</u> and <u>diclofenac</u>.
- 2. Drugs should be given as soon as the onset of an attack is recognised.
- 3. The addition of a gastric motility agent will aid gastric emptying, as well as relieving nausea.
- 4. Anti-migraine drugs containing Metoclopramide are not suitable for patients under the age of 18 years.
- 5. Since peristalsis is often reduced in migraine attacks, dispersible preparations may be helpful.
- 6. Suppositories are useful if vomiting or severe nausea present.

Adult Headache Guideline

Triptans (5HT1-receptor agonists)

Please see Doncaster formulary at

http://medicinesmanagement.doncasterccg.nhs.uk/formulary/formularies/ for further drug information. Try using the most cost-effective preparation first line, current Doncaster formulary triptans are listed below.

Sumatriptan (first line)	Tablets 50, 100mg Injection 6mg per 0.5ml Nasal spray 10mg or 20mg per 0.1ml/dose
Zolmitriptan	Tablets 2.5mg or Melts 2.5, 5mg

Notes:

- 1. NICE recommends that oral triptans should be used first line and other preparations only considered if these are ineffective or not tolerated.
- 2. A second Triptan should not be taken if the first dose is ineffective.
- 3. Triptans are contraindicated in, uncontrolled hypertension, or risk factors for coronary heart disease or cerebral vascular disease.
- 4. Different Triptans have different profiles of 5HT site action. If the first Triptan tried fails, it is worth trying alternative ones. A pragmatic approach would be to choose the cheapest one from each group as a first line.
- 5. Nasal spray is useful when vomiting is a problem.

Prevention of migraine

Prophylaxis is used to reduce the number of attacks in circumstances when acute therapy, used appropriately, gives inadequate symptom control. There are no specific guidelines as to when prophylaxis should be commenced. Considerations include frequency, impact, failure of acute therapy, avoidance of medication overuse headache. The potential for teratogenic effects should be noted particularly with anti epileptic medications. In line with NICE recommendations these updated guidelines no longer include a recommendation to use pizotifen. Additionally propranolol is now recommended first line again in line with NICE recommendations and licensed indications.

Notes:

- 1. Propranolol is the β -blocker of choice but Atenolol is an alternative (unlicensed indication).
- 2. Start at the lowest dose and build up gradually. Maintain the maximum tolerated dose for a minimum of 6 weeks before assessing. Discuss with patient at 6 months whether a gradual reduction and elimination of prophylactic medication might be considered.
- 3. Amitriptyline is useful with co-existent tension type headache, disturbed sleep or depression.

Adult Headache Guideline

<u>Topiramate</u>

Topiramate is licensed for migraine prophylaxis in adults, and it is now recommended for use in the NICE headache clinical guideline.

Topiramate tablets are now available generically and should be prescribed in preference to sprinkle capsules due to price difference.

Costs (Drug Tariff November 2016)

Topiramate tablets	Topiramate sprinkle capsules
25mg x 60 £1.69	(Topamax [®])
50mg x 60 £2.01	25mg x 60 £14.55
	50mg x 60 £55.60
	Ű,

The SPC (summary of product characteristics) will have full information on cautions, contra-indications and side effects.

Place in therapy

This will be tailored to each patient, but as highlighted in the headache pathway, it should be considered when

- The frequency of migraines is such that regular prophylaxis is warranted
- A suitable trial of first line prophylactic medication (β-blockers and/or amitriptyline) have failed to offer relief of symptoms
- Second line therapy is Topiramate

Review

Continuing therapy should be reviewed every 6 months.

Dose

Note can take 6-8 weeks before maximum effect gained.

Commence topiramate at 25mg nightly, and increase (see below) if required.

Titration Schedule

The dosage should then be increased in increments of 25 mg/day administered at 1week intervals. If the patient is unable to tolerate the titration regimen, longer intervals between dose adjustments can be used.

Some patients may experience a benefit at a total daily dose of 50 mg/day. The recommended total daily dose of topiramate as prophylactic treatment of migraine headache is 100 mg/day administered in two divided doses. No extra benefit has been shown from the administration of doses higher than 100 mg/day.

Topiramate Dosage	Morning	Evening
Week 1		25mg
Week 2	25mg	25mg
Week 3	25mg	50mg
Week 4	50mg	50mg

Contraindications

Known hypersensitivity Breast feeding Pregnancy

Cautions

Avoid abrupt withdrawal Hepatic impairment Renal impairment Topiramate has been associated with acute myopia with secondary angle closure glaucoma, typically occurring within 1 month of starting treatment. Choroidal effusions have also been reported. If raised intraocular pressures occur – seek ophthalmology advice and stop topiramate as rapidly as possible

Side Effects

Nausea, dyspepsia and diarrhoea Dry mouth and taste disturbance 25% of people experience anorexia/loss of appetite Drowsiness, insomnia, dizziness 50% of people experience initial paraesthesia (which usually settles)

Rarely - reduced sweating metabolic acidosis and alopecia Very rarely - leucopenia, thrombocytopenia and serious skin reactions

Interactions

Oestrogens – metabolism accelerated – reduced contraceptive effect Progestogens – metabolism accelerated – reduced contraceptive effect Glibenclamide – possibly reduces plasma concentrations Lithium – possibly affects plasma concentration

For further information on contraindications, precautions, adverse effects and interactions refer to the BNF or <u>Summary of Product Characteristics</u>,

Adult Headache Guideline

Useful Resources – these guidelines have been developed using NICE and BASH guidelines below

1) NICE 2012 Headaches – Diagnosis and management of headaches in young people and adults. Clinical guideline 150

2) The British Association for the Study of Headache (BASH) are the main source of these guidelines, and they have more information at www.bash.org.uk/

3) Migraine in Primary Care Advisors is another useful web-site with guidance and information on further education www.mipca.org.uk/

4) The International Headache Society http://ihs-classification.org/en/

Self Help Resources

Patient UK – www.patient.co.uk

Migraine Action association - http://www.migraine.org.uk/index.aspx

Migraine Trust - http://www.migrainetrust.org/

Organization for the understanding of cluster headaches - http://www.ouchuk.org/

About this Guideline

Authors Dr Khaimraj Singh – GP and Right Care clinical lead for Neurology DCCG Emma Smith- Support Manager DCCG

Contributor Medicines Management Group on the prescribing element of the document

Final Approved Publication January 2017 Pathway Amendment March 2018 Review Date September 2018